Ana Analyst st Presenta esentatio tion 3Q 3Q18 & 9M 18 & 9M18 R 18 Result ults 15 November 2018
Disclaimer This presentation and all other information, materials or documents provided in connection therewith, must not be photocopied or reproduced or distributed to any other person in whole or in part at any time except with Praram 9 Hospital Public Company Limited (“ PR9 ”) prior written consent. These materials have been prepared by PR9 solely for use at a presentation for this meeting. No representations, warranties, or undertakings, express or implied, are made by PR9, or any of their respective members, directors, officers, employees, agents, affiliates, advisers or representatives or any other person as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of, the information or opinions presented or contained in these materials. By attending this presentation, you are agreeing to be bound by the restrictions set out below. Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The contents of these materials have not been verified by PR9 and it may not contain all material information concerning PR9. None of PR9, or any of their respective directors, officers, employees, agents, affiliates, advisers or representatives accepts any liability whatsoever in negligence or otherwise for any loss howsoever arising, whether directly or indirectly, from any use of the information or opinions presented or contained in these materials or otherwise arising in connection with these materials. The information and opinions presented or contained in these materials are provided as at the date of this presentation based on the economic, regulatory, market and other conditions as in effect on the date hereof and are subject to verification, completion, updating, revision and change without notice and the accuracy of the information is not guaranteed. It should be understood that subsequent developments may affect the information and opinions presented or contained in these materials, which neither PR9 nor its advisers or representatives are under an obligation to update, revise or affirm. This presentation may contain “forward-looking statements” as well as “unaudited forecasts” and “projected financial information” (“ Forward-Looking Statements ”), which (i) address hypothetical situation, (ii) are based on current expectations and projections about future events, or (iii) include all statements other than statements of historical facts, as well as predictions, projections and forecasts of the economy or economic trends of the markets. Such Forward-Looking Statements are not necessarily indicative of the future or likely performance or projection of PR9 and involve known and unknown risks, uncertainties and other important factors beyond the control of PR9 that could cause the actual results, performance or achievements or industry results to be materially different from future results, performance or achievements expressed or implied by such Forward- Looking Statements. Such Forward-Looking Statements are based on forecasts and projections from PR9. Forward-Looking Statements are not guarantees of future performance and speak only as at the date of this presentation, and none of PR9, or any of their respective directors, officers, employees, agents, affiliates, advisers or representatives intends or has any obligation or undertakes to supplement, amend, update or revise any forward-looking statements as a result of new information or to reflect future events or circumstances, except as required under applicable laws. You should not place undue reliance on these Forward-Looking Statements. Past performance is not necessarily indicative of future performance. No part of this presentation and the information contained in these materials shall constitute or form part of any advertisement of, commitment or offer or invitation of any offer for sale or subscription of or solicitation or recommendation or invitation of any offer to buy or subscribe for, any securities of PR9 in any jurisdiction nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No consideration has been given to particular investment objectives, finances or needs of any recipient. This presentation should not be treated or relied upon as advice relating to legal, taxation, financial, accounting, investment matters or advice or a credit or other evaluation of the offering for any securities of PR9. By attending this presentation you (i) acknowledge that you will be solely responsible for your own assessment of the market and the market position of PR9, and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of PR9’s business and (ii) agree to be bound by the foregoing terms PR9 and its representatives are not responsible for any costs or expenses incurred by the recipient. Note: Analyst Presentation 3Q18 & 9M18 Results as of 15 November 2018 1
Agenda 1 Overview 2 PR9 Summary and Updates 3 Operational Statistics & Financial Performance 4 Project Updates 2
Agenda 1 Overview 2 PR9 Summary and Updates 3 Operational Statistics & Financial Performance 4 Project Updates 3
Vision & Milestones Started hospital Started using 500 Kidney Transplant Started new building Listed in the operation 4D Ultrasound Cases construction Stock Exchange of Thailand 1992 2001 2004 2005 2013 2016 2017 2018 1 st private hospital with 1 st private hospital with THB 200 mm Implementation of Signed Kidney Rights offering 64 Slice CT Scan Pharmacy Robot 640 Slice CT Scan referral MOUs Vision The Most Trusted State of the Art Healthcare Provider Providing the Best Healthcare Solution for Prevention and Treatment that Mission are Valuable for Money by Professional Using State of the Art Technology Values Accountability Teamwork Professionalism 4
Overview Tertiary-care hospital with world class medical quality (both general and complex treatments) 22 Comprehensive Medical Centers ü 2010/ 2013/ 2016 – JCI 3 rd accredited Accreditation ü 2016 - CCPC: Kidney Medical ü 2016 - CCPC: Diabetes medical care Cardiovascular Kidney Transplant Institute Institute ü 2004/ 2007 - HA Level 3 ü 2000 - ISO 9001:1994 Breast Clinic, Diabetes Metabolic Praram 9 ü 2003 - ISO 9001:2000 Praram 9 Hospital Center Hair Center Obstetric Mind Center Orthopedic Technology − 2017 : 640-slice CT Scan Gynecology Center Center − 2016 : Pharmacy Robot − 2005 : 64-slice CT Scan Eye Center Surgery Center Pediatrics Center − 2004 : 4D Ultrasound Medical Center Dental Center Check-Up Center 2018 : Thailand Top Company Awards 2018 (Healthcare Sector) Imaging Center Ear Nose and Achievements Rehabilitation Center Business+ magazine & University of the Thai (X-Ray) Throat Center Other key Chamber of Commerce Gastroenterology Skin Rejuvenation (GI) Cosmetic Laser 2017 : Best Utilization Award Neurology and Hepatobiliary Surgery & AXA Provider Award Center (Liver) Dermatology Center 2017 : Fertility Service Provider of the Year X Emergency Center Thyroid Center Global Health and Travel Awards 2017 5
PR9 Key Strategies 2018 2019E 2020E 2021E 2022E n 21 step down n 77 normal ward n 24 ICU/CCU n 21 normal ward n 21 normal ward ICU beds beds beds beds beds Scope and Scale n Comprehensive n Pain and Rehab ü Leverage expertise to build new customers base Expansion Center medical check- n Metabolic Syndrome ü Enhance medical treatment quality in the long term up program Care Center n Allergy Center ü Hospital Network Expansion and Medical Cooperation Top Line ü Increase Corporate and Insurance Coverage Initiatives ü International Patients Expansion ü Increase capacity utilization which will result in lower unit cost Margin ü Increase service intensity Expansion ü Digital Hospital Transformation Revitalizing Brand Awareness 6
Capacity Addition (New Facility and Renovation of Existing Facility) Scale and scope of services expansion Where we are today Where we want to be Recognized complex medical treatments providers Offer Comprehensive Medical Services Health Promotion/ Disease Prevention / Curative Medicine / Rehabilitation A B Renovated Existing Building New Building (Chronic) (Wellness) Health Disease Curative Usable New capacity addition (1) Rehabilitation Promotion Prevention Medicine Area c. 57,325 sq.m Step Normal Wards Leverage expertise to build new customers base ICU and ü Down NICU Total CCU (A) (B) ICU One Stop Service Check-up Center n Metabolic Syndrome Care Center 2017 - 24 122 - 3 149 n Allergy Center 2018E 21 (3) 24 122 - 3 170 n Pain and Rehabilitation Center n 2019E 21 24 140 59 (2) 3 247 2020E 21 48 (3) 140 59 3 271 Increase intensity of existing customers ü 2021E 21 48 161 59 3 292 Enhance medical treatment quality in the long term ü 2022E 21 48 182 59 3 313 (1) The actual active beds will be phasing subject to demand and business situations. (2) Expected completion of new building with the maximum new bed capacity of 59 beds in 1Q2019. 7 (3) Step down ICU and additional ICU/CCU capacity expected completion are on 4Q2018 and 3Q2020 respectively
Recommend
More recommend
